Status:
RECRUITING
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Myelofibrosis
Primary Myelofibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of...
Detailed Description
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice.
- Availability of data on clinical history prior to initiation of Ruxolitinib therapy
- Obtaining informed consent for data collection and processing
Exclusion
- None
Key Trial Info
Start Date :
May 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2032
Estimated Enrollment :
1055 Patients enrolled
Trial Details
Trial ID
NCT06516406
Start Date
May 6 2022
End Date
May 31 2032
Last Update
December 5 2024
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Annunziata
Cosenza, Calabria, Italy, 87100
2
Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
Reggio Calabria, Calabria, Italy, 89124
3
Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo
Napoli, Campania, Italy, 80131
4
IRCCS Policlinico Sant'Orsola
Bologna, Emilia-Romagna, Italy, 40138